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Abstract
The SLIT2-ROBO1/2 pathways control diverse biological processes, including growth regulation. To understand the role of
SLIT2 and ROBO1/2 in cervical carcinogenesis, firstly their RNA expression profiles were screened in 21 primary uterine
cervical carcinoma (CACX) samples and two CACX cell lines. Highly reduced expressions of these genes were evident.
Concomitant alterations [deletion/methylation] of the genes were then analyzed in 23 cervical intraepithelial neoplasia (CIN)
and 110 CACX samples. In CIN, SLIT2 was deleted in 22% samples compared to 9% for ROBO1 and none for ROBO2, whereas
comparable methylation was observed for both SLIT2 (30%) and ROBO1 (22%) followed by ROBO2 (9%). In CACX, alteration
of the genes were in the following order: Deletion: ROBO1 (48%). SLIT2 (35%). ROBO2 (33%),Methylation: SLIT2 (34%).
ROBO1 (29%) . ROBO2 (26%). Overall alterations of SLIT2 and/or ROBO1 (44%) and SLIT2 and/or ROBO2 (39%) were high in
CIN followed by significant increase in stage I/II tumors, suggesting deregulation of these interactions in premalignant
lesions and early invasive tumors. Immunohistochemical analysis of SLIT2 and ROBO1/2 in CACX also showed reduced
expression concordant with molecular alterations. Alteration of all these genes predicted poor patient outcome.
Multiparous ($5) women with altered SLIT2 and ROBO1 along with advanced tumor stage (III/IV) and early sexual debut
(,19 years) had worst prognosis. Our data suggests the importance of abrogation of SLIT2-ROBO1 and SLIT2-ROBO2
interactions in the initiation and progression of CACX and also for early diagnosis and prognosis of the disease.
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Introduction
On worldwide basis, uterine cervical carcinoma (CACX) is the
second common gynecological cancer, mostly afflicting the
developing nations like India [1–3]. Among Indian women CACX
ranks second, next only to breast cancer [4]. High-risk Human
Papilloma Virus (HPV) is an important etiological agent associated
with CACX [5]. It is transmitted sexually and is consequently
ubiquitous among sexually active women. Therefore determinants
of sexual activity namely; parity, age at sexual debut etc
significantly predicts the risk to CACX [6]. Existing evidences
indicated an intricate interplay between HPV infection and
genetic alterations that critically contributes towards cervical
carcinogenesis [7].
Different chromosomal abnormalities namely; deletion, ampli-
fication, rearrangement etc involving several chromosomal regions
were reportedly associated with the development of CACX [7–
11]. Our previous study reported frequent deletion (35–38%) and
methylation (52%) of SLIT2, located at chr. 4p15.31, in CACX of
Indian patients [12]. Whereas, predominant hypermethylation
(64%) and infrequent deletion (9%) of the same was reported in
CACX of Western patients [13]. In normal non-neuronal cells,
SLIT2 is a secreted tumor suppressor protein that through binding
of its cognate receptors ROBO1/2 and via inhibition of WNT,
SDF1 and HGF signaling regulates multiple cellular processes
namely; cell cycle, apoptosis, cell-cell adhesion, cellular motility
and invasion etc [14]. Interaction between SLIT2 and ROBO1/2
causes activation of srGAP molecules and consequent inactivation
of CDC42 (by hydrolysis of bound GTP), leading to cell cycle
arrest at G1-S transition [14]. Similarly, SLIT2-ROBO1/2
interaction relieves the inhibition on DCC receptors by ligand
Netrin-1, leading to activation of apoptosis via caspases-3 and 9
[14]. In the event of abrogation of SLIT2 and ROBO1/2
interactions the cellular surveillance posited in the form of G1-S
checkpoint and apoptosis gets aberrant, giving rise to mutated
forms that has the property of conferring greater growth
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advantage to the cells. This ultimately results in uncontrolled
cellular proliferation and promotion of tumorigenesis.
Alike SLIT2, frequent methylation (46%) and nominal deletion
(10%) frequencies of ROBO1 was reported in CACX of Western
patients [13]. To the best of our knowledge, alterations of ROBO1
have not been studied in CACX of Indian patients. In addition
alterations of ROBO2 localized 1.3 Mb telomeric to ROBO1 at chr
3p12.3 region, have not been studied in details in CACX, though
its alterations have already been reported in head & neck
squamous cell carcinoma [HNSCC] [15].
Intron2 of ROBO1 harbors two non-coding RNAs [ncRNAs;
BC017743 and BC043430], suggesting their probable role in
modulating the expression of ROBO1. The expression pattern of
these ncRNAs in CACX has not yet been studied but their
differential expression has been detected in various carcinomas
like; lung, breast, oral etc [15,16].
Therefore, to understand the importance of SLIT2-ROBO1/2
pathway in the development of CACX, it is pertinent to analyze
the alterations of these genes in the same set of samples. Thus our
study has been focused on the following aspects: (i) quantitative
mRNA expression analysis, (ii) alteration (deletion/methylation)
analysis and (iii) correlation of molecular alterations of the genes
with clinico-pathological parameters (stage, nodes at pathology,
HPV status, parity etc) and patient outcome. Our data revealed
reduced expression and frequent alterations (37–55%) of SLIT2
and ROBO1/2 in primary cervical lesions. In addition, 84% and
80.5% samples showed co-alterations of SLIT2-ROBO1 and
SLIT2-ROBO2 pairs respectively, indicating the importance of
these ligand-receptor interactions in cervical carcinogenesis.
Moreover Cox multivariate analysis revealed alterations of SLIT2
and ROBO1, in combination with advanced tumor stage (III/IV),
multiparity ($5) and early sexual debut (,19 years) as
determinants of worse prognosis.
Materials and Methods
Ethics Statement
The Institutional Ethical board of Chittaranjan National
Cancer Institute, Kolkata approved the usage of Human speci-
mens in this study. The above board approved usage of these
human clinical samples specifically in this study, pertaining to the
involvement of SLIT2-ROBO1/2 signaling in CACX. The tumor
specimens were collected from the hospital section of Chittaranjan
National Cancer Institute, Kolkata, after obtaining written,
informed consent of the concerned patients, in stipulated format,
approved by the above mentioned Institutional Ethical board of
Chittaranjan National Cancer Institute, Kolkata, India.
Clinical Specimens and Cell lines
This study included a total of 133 primary cervical lesions and
corresponding peripheral blood lymphocytes (PBL) collected from
the hospital section of Chittaranjan National Cancer Institute,
Kolkata, after institutional consent. The tumors were graded or
staged according to FIGO classification. Among these samples, 23
were premalignant/CIN lesions (10 low grade CINI and 13 high
grade CINII/III), 56 stage I/II tumors and 54 stageIII/IV tumors
(Table 1). The normal cervical tissues (n = 8) were collected from
patients with clinically normal cervix, but underwent hystectomy
due to other gynecological reasons. These served as controls for
RNA/protein study. The tissues (normal/tumors) were either
frozen to 280uC or taken in TRIzol reagent (Invitrogen, USA) for
RNA isolation or fixed in formalin and paraffin embedded for
Table 1. Clinico-pathological features of cervical lesions.
Clinical features No of Patients Mean age (yrs) HPV Positivity P-value
HPV + HPV - % positivity
Tumor stage 1
CIN 23 36 20 3 87 0.9962
Stage-I 33 47 28 5 85
Stage-II 27 46 24 3 89
Stage-III 43 47 37 6 86
Stage-IV 7 50 6 1 86
Tumor differentiation
Dysplasia 23 36 20 3 87 0.9491
Well 15 48 13 2 87
Moderate 80 45 69 11 86
Poor 15 44 13 2 87
Lymph node
Node+ 32 45 28 4 87.5 0.8450
Node- 101 46 87 14 86
Parity (Live births only)
Low (0–4) 80 48 68 12 85 0.5451
High ($5) 53 47 47 6 89
Age at sexual debut
Early (12–19 y) 73 42 62 11 85 0.5696
Late (.19 y) 60 45 53 7 88
1According to The international federation of gynecology and obstetrics (FIGO) classification.
doi:10.1371/journal.pone.0038342.t001
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immuno-histochemistry (IHC). Clinical/follow-up data of the
patients were collected from the hospital records. Demographic
details were obtained by personally questioning the patients.
The CACX cell lines: SiHa and HeLa were purchased from
National Centre for Cell Sciences, Pune, India and were grown
according to supplier’s instructions.
RNA Expression Analysis
Expression of ROBO1/2, SLIT2 RNAs and the ncRNAs were
analyzed by Q-RT PCR in normal cervical tissue (n = 8), CACX
samples (#T1–#T21) and cell lines: SiHa and HeLa, using
primers given in Table S1. RNA isolation and cDNA preparation
were done as outlined by Mitra et al (2010) [17] and Information
S1. The real time quantitation of RNA expression was done by
Power SYBR-green PCR assay (Applied Biosystems, USA) using
ddCt method [18,19]. The b2-microglobulin was used as the
internal control. Details of this method have been included in
Information S1.
5-aza-dC Treatment of SiHa and HeLa
HeLa and SiHa cell lines were grown in presence and absence
of 5-Aza-29-deoxycytidine (5-aza-dC) for 3–5 days at 5 mM,
10 mM and 20 mM concentrations. The cells were harvested
followed by RNA isolation, cDNA preparation and real time
quantitations using Power SYBR-green PCR assay according to
protocols described above [18,19].
Microdissection and DNA Extraction
The clinical specimens comprising mostly of biopsy/surgical
materials, were frozen, sectioned in cryomicrotome (5 mm), stained
with hematoxylin-eosin and then the contaminant normal cells
were removed by microdissection [20] under dissecting micro-
scope (Leica MZ 16, Germany). Microdissected samples contain-
ing .60% dysplastic epithelium/tumor cells were taken for DNA
isolation according to the standard procedure [20,21]. Details in
Information S1.
Promoter Methylation Analysis
Methylation sensitive restriction analysis (MSRA) was per-
formed to screen promoter methylation status of SLIT2 and
ROBO1/2 in a cohort of 23 CIN and 110 CACX samples using
primers listed in Table S1 [22]. Among these samples, 17 CIN and
41 CACX samples have already been analyzed for SLIT2
methylation by a previous study of our laboratory [12]. The
methylation sensitive HpaII and its methylation insensitive
isochizomer MspI have been used in the analysis. The b-3A
adaptin gene (K1) was used as digestion control and RARb2 (K2)
served as the control for DNA integrity [22].
Methylation analysis was validated in 20 (2 CIN and 18 CACX)
randomly selected samples by methylation-specific-PCR (MSP)
after bisulphite modification of DNA using primers listed in Table
S1B. The genomic DNA (5 mg) was subjected to bisulphite
modification followed by PCR amplification of the modified DNA
using primers for non-methylation (U) or methylation (M) specific
alleles [23]. Details of MSRA/MSP protocols have been included
in Information S1.
Deletion Analysis
Deletion of the ROBO1/2 and SLIT2 loci were done in 23 CIN
and 110 CACX samples, using microsatellite and exonic markers
[12,15]. Among these, 17 CIN and 41 CACX samples were
previously analyzed only (not ROBO1/2) for SLIT2 deletion [12].
In total, 6 microsatellite and 2 exonic markers [(Ensembl release
49; Genome Database); Details in Table S1] were chosen. Among
them D3S3507, D3S1274 and D4S1546 were informative (high
polymorphic) and the rest were non-informative. The details of the
deletion analysis have been included in Information S1. Scoring of
loss of heterozygosity [LOH]/deletion and microsatellite size
alteration [MA] for informative/non informative markers were
done according to standard protocols [12,20,24] Details in
Information S1.
Immunohistochemical and Immunocytochemical
Analysis
Protein expression of ROBO1/2 and SLIT2 was studied by
immunohistochemistry (IHC) in normal cervical tissue (n = 8) and
primary CACX (n=15) using primary antibodies [Goat poly-
clonal IgG sc-16611, sc-16615 and sc-16619 for ROBO1,
ROBO2 and SLIT2 respectively] and HRP-conjugated rabbit
anti-goat secondary antibody (sc-2768) from Santa Cruz Bio-
technology, CA, USA, following standard protocols (Information
S1). The scoring of staining frequency and intensity was done
according to Perrone et al [2006] [25]. The expression of these
proteins in SiHa and HeLa cells were studied by immunocyto-
chemistry. The cells were cultured on coverslips till sub-
confluency, fixed with methanol, blocked with BSA, incubated
with respective primary antibodies (as above) followed by
fluorescein isothiocyanate (FITC)-conjugated secondary antibody
(sc-2777), washed and briefly incubated with DAPI (sc-3598) and
subsequently mounted on slides, viewed and photographed by
fluorescence microscope (Leica DM 4000B; Germany) [17].
Detection of HPV-16 and HPV-18
Presence of HPV in the cervical lesions were detected by PCR
using primers (MY09 and MY11) from the consensus L1 region
followed by typing of HPV 16/18, frequent oncogenic variants, in
the L1 positive samples [26].
Statistical Analysis
The x2 analysis determined the association of genetic profile of
tumors (alteration of ROBO1/2, SLIT2) with different clinico-
pathological parameters. Survival curves were obtained according
to Kaplan–Meier method. Cox proportional hazards regression
model predicted the significant determinants (genetic/epidemio-
logical) of patient’s survival. Overall survival (OS) was measured
from the date of surgery to the date of most recent follow-up or
death (upto 5 years). Consistent follow-up records were available
for 86 CACX patients with mean and median follow-up of 14610
months and 10 months respectively. Only these patients were
included in the Cox and Kaplan–Meier survival analyses.
Probability value (P-value) #0.05 was considered statistically
significant. SPSS was used to perform all the statistical analyses
(SPSS Inc. Chicago, IL, USA).
Results
Expression Pattern of SLIT2 and ROBO1/2 in CACX
In quantitative RT-PCR analysis, fold reduction in expression
of the genes in CACX were in the following order: SLIT2
(8.865.2) . ROBO1 (862.3) . ROBO2 (7.465.6). About 48–57%
tumors showed reduction greater than the mean value of
expression of the respective genes (Figure 1A,B). Similar trend
(except for ROBO1) was observed for the CACX cell lines SiHa
and HeLa, in the following order: SiHa: SLIT2 (38 folds) .
ROBO2 (29 folds), HeLa: ROBO2 (80 folds) . SLIT2 (2.8 folds)
(Figure 1A,B). Thus, transcriptions of SLIT2 and ROBO1/2 were
severely impaired during cervical carcinogenesis.
Frequent Alterations of SLIT2-ROBO1/2 in CACX
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Similarly the expressions of the two ncRNAs were also reduced
in both primary CACX and cell lines in the following order:
BC043430 (5.863.14) . BC017743 (362.9) (Figure 1A,B). The
ncRNA BC017743 showed 2 folds reduction in SiHa and
BC043430 showed 26 folds reduction in HeLa, though ROBO1
was not reduced in any of the cell lines. A comparison of
expression levels (ddCt) of the ncRNAs versus ROBO1, showed
frequent, relatively more reduced expression of ROBO1 (data not
shown), in the primary tumors. These facts probably suggest that
the ncRNAs and ROBO1 were transcribed from separate
promoters.
Frequent Promoter Methylation of SLIT2-ROBO1/2 in CIN
and CACX
To understand the mechanism of impaired expression of SLIT2
and ROBO1/2 in cervical lesions, the promoter methylation status
of these genes were analyzed. In CIN, methylation frequencies of
SLIT2 (30%, 7/23) and ROBO1 (22%, 5/23) were high, followed
by ROBO2 (9%, 2/23) (Figure 1C, Table S2A,C). In CACX, the
methylation frequencies of SLIT2 (34%, 37/110) and ROBO1
(29%, 32/110) were comparable to CIN, though there was
substantial increase in methylation frequency of ROBO2 (26%, 29/
110) (Figure 1C, Table S2B,D). In SiHa and HeLa cells, ROBO2
was methylated, whereas SLIT2 was methylated only in SiHa.
Methylation of ROBO2 in CACX was not reported earlier. The
promoter methylation statuses of the ligand-receptor genes were
confirmed in 20 (2 CIN and 18 CACX) randomly selected samples
by MSP and the results were concordant with MSRA (Figure 1C3,
Table S5).
About, 15.5% (17/110) and 13% (14/110) of the CACX
samples showed methylation exclusively for ROBO1 and ROBO2
respectively, indicating that none of the events were epiphenom-
ena (Table S2B). However, significant association was also found
between the methylation statuses of ROBO1 and ROBO2 in both
CIN and CACX (Table S3A), suggesting their possible coopera-
tivity during cervical carcinogenesis.
In case of SLIT2 and ROBO1 methylation was frequent (20–
30%) in premalignant CIN lesions and remained comparable
thereafter (Figure 2D). However, the methylation frequency of
ROBO2 increased gradually from CIN to subsequent stages of
tumorigenesis, indicating that methylation was a late event for
ROBO2 inactivation (Figure 2D). Thus, promoter methylation of
Figure 1. Comparative representation of RNA expression of (A) ROBO1, ROBO2 & SLIT2 and (B) ROBO1, BC017743 & BC043430 in
CACX. Bars represented the gene expression normalized to b2- microglobulin and relative to a pool of normal cervical tissues, using the 2ˆ-ddCt
method. Bars 22 and 23 represent the SiHa and HeLa cell lines, respectively. Analysis of promoter methylation of ROBO1/2 and SLIT2 by MSRA and
validation by MSP. (C1) Schematic representation of promoter regions of candidate genes revealing distribution of HpaII/MspI (CCGG: arrowhead)
restriction sites. R: location of methylation primers. +1: transcription start site. (C2) Representative tumor samples (#3920T, #3229T, #4025T)
showing methylated status at different genes, normal cervical tissue were unmethylated. M and H: MspI and HpaII digested DNA respectively. U:
Undigested DNA. K1 and K2: Controls for DNA digestion and integrity respectively, T: Tumor DNA, N: DNA from corresponding normal tissue. (C3)
Representative tumor samples showing methylation status of candidate genes by MSP. U: amplicon obtained with primer for bisulphite modified
unmethylated DNA, M: amplicon obtained with primer for bisulphite modified methylated DNA, T: Tumor DNA, N: DNA from corresponding normal
tissue. (D) Reactivation of RNA expression of ROBO1 and the ncRNAs in SiHa and HeLa cells. Reactivated RNA expression of the ligand-receptor genes
in SiHa (E) and HeLa (F) cell lines in presence of 5 mM, 10 mM and 20 mM 5-aza dC. The bars represent increased gene expression in 5-aza dC treated
cells compared to untreated control.
doi:10.1371/journal.pone.0038342.g001
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SLIT2 and ROBO1/2 might account for the lowered expression of
these genes during cervical carcinogenesis.
Validation of Promoter Methylation of the Genes by 5-
Aza Deoxycytidine
To confirm if downregulation of the SLIT2, ROBO1/2 and
ncRNAs were due to methylation, demethylation experiment was
performed by treatment of SiHa and HeLa cells with 5-Aza
Deoxycytidine (5-aza dC). Dose dependent reactivation of SLIT2
and ROBO1/2 expression was observed in the cell lines w.r.t
untreated controls. At the high 20 mM 5-aza dC concentration
increase in expression frequencies were as follows: SiHa: SLIT2
(14.5) . ROBO2 (2.6) . ROBO1 (2.1) . BC043430 (1.8) .
BC017743 (1.7) and HeLa: ROBO2 (4.6) . BC043430 (3) .
SLIT2 (2.8) . BC017743 (2.5) . ROBO1 (1.9) (Figure 1D–F).
The comparatively high expression of ROBO2 in both cell lines
and SLIT2 in SiHa were in concordance with their methylation
statuses. Differential increase in expression of ROBO1 and
ncRNAs in both the cell lines, re-affirms transcription of these
genes from different promoters. Thus, our data validates promoter
methylation as one of the inactivating mechanisms of SLIT2 and
ROBO1/2 in CACX development.
Frequent Deletion of SLIT2 and ROBO1/2 loci
Genetic mechanisms like deletion, often results in inactivation of
the candidate TSGs. In CIN lesions, deletion frequency of SLIT2
was high (22%, 5/23) followed by ROBO1 (9%, 2/23). However,
ROBO2 showed no deletion (Figure 2B, Table S2A,C). In CACX,
ROBO1 was highly deleted (48%, 53/110) followed by SLIT2
(35%, 38/110) and ROBO2 (33%, 36/110) (Figure 2C, Table
S2B,D). None of these loci showed deletion in either SiHa or
HeLa cells.
In CACX, deletion of ROBO2 showed significant association
with ROBO1 and SLIT2 (Table S3B), indicating their correlation
in this carcinogenesis. The deletion of ROBO2 is not an
epiphenomenon of deletion of ROBO1 as 11% (12/110) of the
CACX samples showed deletion only of ROBO2 (Table S2B).
Microsatellite size alterations (MA) of ROBO1 and SLIT2 were
infrequent in cervical tumors (Table S2A–D), unlike HNSCC (15).
No homozygous deletion but other types of biallelic alterations
[LOH+MA, MAII] was evident for SLIT2 and ROBO1 loci (Table
S2A–D). The deletion frequency of SLIT2 increased gradually
during tumor progression (Figure 2D). However, in case of ROBO1
there was significant increase in deletion frequency from CIN to
stage I/II tumors and for ROBO2, frequency of deletion was high
in stage I/II tumors and remained comparable in the subsequent
Figure 2. Representative autoradiographs showing deletion and microsatellite size alteration (MA) of cervical lesions, at different
marker loci. (i) LOH: loss of heterozygosity, (ii) MA-1: microsatellite size alteration of one allele. (iii) LOH + MA: loss of one allele and microsatellite
size alteration of the other. (iv) Hemizygous (HE) deletion of ROBO2 locus as shown by D3S2515. (v) & (vi) HE deletion as shown by exonic markers
(EM) from ROBO1 and ROBO2 respectively, SST used as control. The sample numbers and marker loci are indicated above and below the figure
respectively.R: allelic loss, ‘‘*’’: allelic size alteration. Deletion of ROBO1/2 and SLIT2 analyzed by microsatellite and exonic markers in (B) CIN and (C)
CACX. T: Tumor DNA, N: DNA from normal cervix/PBL. (D) Pattern of deletion and methylation of ROBO1/2 and SLIT2 during disease progression.
Asterisk denotes statistical significance (P,0.05). (E) Overall alteration patterns of the individual genes, SLIT2-ROBO1 and SLIT2-ROBO2 ligand-receptor
pairs, during disease progression. Asterisk denotes statistical significance (P,0.05).
doi:10.1371/journal.pone.0038342.g002
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stage (Figure 2D). These facts indicate that deletion was a late
event during inactivation of the receptor genes and contributed
towards inactivation of both SLIT2 and ROBO1/2 in CACX.
Overall Alterations of SLIT2 and ROBO1/2
Majority of the tumors (86%; 74/110) showed (epi) genetic
alterations in at least one of the SLIT2 and/or ROBO1/2 genes,
indicating their importance in cervical tumorigenesis. The overall
alterations (deletion/methylation) of these genes in CIN and
CACX were in the following order: CIN: SLIT2 (35%; 8/23) .
ROBO1 (22%; 5/23) . ROBO2 (9%; 2/23) (Figure 2E, Table
S2A,C); CACX: SLIT2 (59%; 65/110) . ROBO1 (58%; 64/110)
. ROBO2 (43%; 47/110) (Table S2B,D).
Significant association between deletion and methylation of
SLIT2 and ROBO1 in CIN, ROBO1 and ROBO2 in CACX and
marginal significance of SLIT2 in CACX were in concordance
with Knudson’s modified two-hit hypothesis for candidate TSGs
(Table S4).
The alterations of SLIT2 were frequent (35%) in CIN lesions
and increased gradually during subsequent stages of tumorigenesis
(Figure 2E). However, for both ROBO1 and ROBO2, alteration
frequencies increased significantly from CIN to stage I/II tumors
and remained comparable thereafter (Figure 2E), indicating that
alterations of the receptors were late event during cervical
carcinogenesis.
Overall alterations of ROBO1 and ROBO2 showed significant
association in CIN and CACX, whereas SLIT2 and ROBO1 in
CACX, suggesting their functional cooperativity in regulating the
signaling pathways (Table S3C). Frequent alterations of SLIT2
and/or ROBO1 were seen in CIN (44%; 10/23) followed by
significant increase in stage I/II (93%; 52/56) and stage III/IV
tumors (93%; 50/54) (Figure 2E). Similar was the trend for SLIT2
and/or ROBO2 alterations (Figure 2E). This suggests that de-
regulation of these ligand-receptor interactions might have
important role in the development of both premalignant cervical
lesions and early invasiveness of the disease.
Analysis of SLIT2 and ROBO1/2 Protein Expression
The association of alterations (deletion/methylation) and RNA
expressions of SLIT2 and ROBO1/2 with their protein expressions
was studied in primary CACX and the cell lines: SiHa and HeLa.
In IHC analysis, expression of ROBO1/2 and SLIT2 were
observed in the membrane and cytoplasm of the basal and
parabasal layers of normal cervical epithelium and comparatively
low expression in the spinous layer (Figure 3AI–III). The primary
tumors without alterations (deletion/methylation) of these genes
showed expression of these proteins similar to the basal/parabasal
layers. However, significant association was seen between re-
duced/no expression of the proteins with their molecular
alterations (Figure 3BI–III, Table 2).
SLIT2 and ROBO2 expressions were reduced in SiHa and
HeLa cells. Expressions of ROBO1 and ROBO2 were observed
with some discrete foci on the membrane of SiHa cells
(Figure 3CI–III). Similar localizations of these proteins were seen
in HeLa, without any focus formation (Figure S1). This might be
due to some modifications of these receptors in SiHa, leading to
their aggregation on the membrane and subsequent dysfunction of
the downstream pathway(s). Cytoplasmic expression of SLIT2 was
observed in SiHa cells, in concordance with the reports of Singh
et al [2007] (12), in HeLa. In primary tumors, reduced/no
expression of SLIT2 and/or ROBO1 was found in 93% (14/15)
samples and of SLIT2 and/or ROBO2 in 67% (10/15) (Table 2),
indicating the deregulation of these ligand-receptor(s) interactions
as critical events in cervical carcinogenesis.
Clinico-pathological Association of SLIT2 and ROBO1/2
The alterations of SLIT2 and ROBO1/2 were correlated with
the clinico-pathological/survival parameters in order to uncover
their prognostic significance (if any) for early diagnosis and
prediction of patient outcome. HPV, an important causative
agent of CACX, was detected in 86.5% (115/133) of the
cervical lesions. Of these, 88% (101/115) were HPV16 positive
and 12% (14/115) were HPV18 positive. HPV infection was
not significantly associated with tumor stage, grade, nodal status,
parity, age at sexual debut (Table 1) and SLIT2-ROBO1/2
alterations (data not shown). Similarly, chi-square analysis
revealed significant association of SLIT2-ROBO1/2 alterations
with tumor stage, however no such associations were observed
with the other clinico-pathological parameters (grade, nodal
status, parity etc; data not shown).
The Kaplan-Meier (K–M) survival analysis revealed significant-
ly reduced overall survival (OS) of CACX patients with alterations
of SLIT2, ROBO1 and ROBO2 (Figure S2A–C), indicating their
prognostic significances. Interestingly, alterations of SLIT2 and/or
ROBO1 and SLIT2 and/or ROBO2 predicted poor OS of the
patients, suggesting abrogation of these ligand-receptor interac-
tions were directly equated to poor prognosis (Figure 4A,B). The
Cox multivariate analysis indicated that alterations of SLIT2 and
ROBO1 along with advanced tumor stage (III/IV), multiparity
($5) and early sexual debut (,19 years) were determinants of poor
prognosis for CACX patients (Figure 4C), thereby enabling
efficient classification of the high-risk patients.
Discussion
The aim of this study was to investigate the association of
ligand-receptor genes SLIT2 and ROBO1/2 in cervical carcino-
genesis. To this end, at first, expression (RNA) profiles of these
genes were analyzed in primary CACX samples and CACX cell
lines. Highly reduced expressions of these genes were revealed.
Then alterations (deletion/methylation) of the genes were
analyzed to understand the mechanism of reduced expression.
Alterations of the genes were then correlated with their
expression (RNA and protein) profile. In addition molecular
alterations of the genes were correlated with different clinico-
pathological parameters. Reduced RNA and protein expression
of SLIT2 and ROBO1/2 were observed in primary CACX, in
concordance with the previous reports [12,13]. However, none
prior to us reported the expression pattern of SLIT2, ROBO1
and ROBO2 concomitantly in primary CACX. Alike us
reduced expression of these genes were also reported in
a plethora of other malignancies including HNSCC, gliomas
and carcinomas of liver, lung, breast, kidney etc [15,27–33].
However, overexpression of these genes were also reported in
prostate and breast cancers [34,35]. In addition, Angeloni et al.,
(2006) [16] suggested that expression of ROBO1 could be
regulated by two ncRNAs encoded by the intron2 of ROBO1.
However, our data suggested that there was no concordance
between the expression profiles of ROBO1 and the ncRNAs, as
observed in HNSCC [15].
Overall alterations of atleast one member of the SLIT2-ROBO1/
2 cascade were observed in 43% CIN lesions and 95% CACX,
indicating the importance of deregulation of this pathway for
cervical carcinogenesis. Alterations of SLIT2 was observed in 35%
CIN lesions with the frequency increasing gradually in subsequent
stages, indicating this as an early event, in concordance with the
reports of Narayan et al., (2006) [13]. In addition deletion or
methylation mediated deregulation of SLIT2 has already been
reported in various malignancies including gliomas, neuroblasto-
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ma, Wilm’s tumor, leukemia and carcinomas of lung, breast,
kidney, colon etc though, none reported the stage wise correlation
pattern [15,28–30,33,36–40]. The alteration frequencies of
ROBO1 and ROBO2 increased significantly from CIN to stage I/
II tumors, indicating that these receptors were inactivated during
the development of early invasive cervical tumors. Alike SLIT2,
Figure 3. Immunohistochemical staining patterns of ROBO1, ROBO2 and SLIT2. (A) In normal cervical epithelium the basal and parabasal
layer stained intensely for all the three proteins, whereas the intensity and frequency of stained cells reduced with further differentiation in the
spinous layer. (B) In primary CACX expression pattern of these proteins were concordant with respective molecular alterations. (C) In SiHa cells
ROBO1 and ROBO2 were membrane localized, whereas SLIT2 was present mostly in the cytoplasm. T: primary CACX sample; scale bars for both 20X
and 40X is 50 mm; original magnifications are indicated in parenthesis. Magnification of panel C is 40X.
doi:10.1371/journal.pone.0038342.g003
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deletion or methylation mediated inactivation of ROBO1 have also
been reported in multiple malignancies including lung, breast,
HNSCC etc [15,27,41]. However, alterations of ROBO2 have
been reported only in HNSCC, as yet [15].
In premalignant CIN lesions, alterations of SLIT2 and/or
ROBO1 and SLIT2 and/or ROBO2 ligand-receptor pairs were
observed in 44% and 39% cases respectively, which increased
significantly in the subsequent stage I/II tumors and remained
comparable thereafter. This fact corroborates that abrogation of
the ligand-receptor interaction was necessary for initiation and
progression of CACX. As yet none has comprehensively reported
the importance of loss of these ligand-receptor interactions in
cervical carcinogenesis of Indian patients.
A close scrutiny of the methylation and deletion frequencies of
SLIT2 and ROBO1 during progression of CACX, indicated that
methylation was the more frequent alteration that occurred early
during carcinogenic progression. Although, in case of ROBO2,
promoter methylation was the late event nonetheless, it was
predominant over deletion. Predominant methylation and in-
frequent deletion of SLIT2 (64%, 9%) and ROBO1 (46%, 10%)
were also reported in CACX of Western patients [13]. The
deletion analysis was done in a cohort of 30 tumors compared to
133 in our analysis, thus accounting for the difference in results
between the two studies [42]. Similarly the methylation frequency
of SLIT2 in our study was 34% and differed widely from that
reported by Narayan et al., (2006) [13], possibly due to age,
ethnicity and lifestyle variation of the patients included in both the
studies [42–44].
The interaction between SLIT2 and ROBO1 triggers a number
of downstream pathways, controlling diverse cellular processes
namely; cell proliferation, apoptosis, motility etc [14]. The most
prominent effectors includes srGAP, CDC42, b-catenin, Netrin-1,
PI3K, CXCR4 etc [14,45]. Detailed study of each of these
pathways is warranted for identification of diagnostic or thera-
peutic targets of CACX, from among the effector molecules of the
SLIT2-ROBO1 signaling pathway.
In this study molecular alterations of the individual genes,
SLIT2 and/or ROBO1 and SLIT2 and/or ROBO2 pairs showed
Table 2. Correlation between deletion/methylation and reduced expression (RNA/protein) of ROBO1/2 and SLIT2 in CIN/CACX.
Sample ROBO1 ROBO2 SLIT2
Del/Meth mRNA Protein Del/Meth mRNA Protein Del/Meth mRNA Protein
T1 D+ Q nd D2, M2 2 nd D+ Q nd
T2 M+ Q Intermediate M+ Q Intermediate D+, M+ Q Absent
T3 D+ Q Low D+ Q Low D+, M+ Q Absent
T4 D+, M+ Q nd D2, M2 q nd D2, M2 2 nd
T5 D+, M+ Q nd D+, M+ Q nd D+, M+ Q nd
T6 D+ Q Low D2, M2 2 Intermediate D2, M2 2 Intermediate
T7 M+ Q nd D+, M+ Q nd D+ Q nd
T8 D+ Q Low D+ Q Absent D+ Q Absent
T9 D2, M2 Q nd D+, M+ Q nd D+, M+ Q nd
T10 D+ Q Low D2, M2 Q Intermediate D2, M2 Q Intermediate
T11 D+ Q nd D+ Q nd D2, M2 Q nd
T12 D+, M+ Q Absent D+ Q Low D+ Q Low
T13 M+ Q nd M+ Q nd D2, M2 Q nd
T14 D2, M2 Q nd D+ Q nd D+ Q nd
T15 D+, M+ Q Absent D+, M+ Q Absent D+, M+ Q Absent
T16 D+, M+ Q nd M+ Q nd M+ Q nd
T17 D+ Q nd D2, M2 2 nd D2, M2 2 nd
T18 D+, M+ Q Low D+, M+ Q Absent D+, M+ Q Low
T19 D2, M2 Q nd D2, M2 2 nd D2, M2 2 nd
T20 D+, M+ Q nd D2, M2 q nd D2, M2 2 nd
T21 D+ Q Low M+ Q Intermediate D2, M2 Q Intermediate
C1 D2, M2 ND Intermediate D2, M2 ND Intermediate D+, M+ ND Low
C2 D2, M2 ND Intermediate D2, M2 ND Intermediate D+, M+ ND Low
C3 D2, M2 ND Intermediate D2, M2 ND Intermediate D2, M2 ND Intermediate
T-24 D2, M2 ND Intermediate D+ ND Low D+ ND Low
T-25 D+ ND Low D2, M2 ND Intermediate D2, M2 ND Intermediate
T-26 D+, M+ ND Low D+, M+ ND Low D2, M2 ND Intermediate
P-value Non-evaluable 0.00016* 0.003*
Samples C1, C2 and C3 are CIN lesions.
D+/2, Deletion (HE, HM, LOH) positive/negative; M+/2, methylation positive/negative; Del/Meth: Deletion or methylation.Q: Reduced mRNA expression ($2 folds);q:
Increased mRNA expression ($2 folds); -: Reduced/Increased mRNA expression (,2 folds). nd, not done due to insufficient/scanty paraffin embedded tumor tissue; ND,
Fresh tissues unavailable for RNA isolation. *, statistically significant (P,0.05).
doi:10.1371/journal.pone.0038342.t002
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differential association with the disease progression and predicted
poor patient outcome. Moreover Cox multivariate analysis
revealed that alterations of SLIT2 and ROBO1 coupled with
advanced tumor stage (III/IV), multiparity ($5) and early sexual
debut (,19 years) were predictors of poor prognosis for CACX
patients.
Thus we can conclude that abrogation of SLIT2-ROBO1 and
SLIT2-ROBO2 signaling pathways are necessary for the initiation
and progression of CACX. Since these ligand-receptor genes
possess prognostic implications, they could be utilized as early
diagnostic or prognostic markers for CACX.
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Figure S1 Immunofluorescence analysis of ROBO1,
ROBO2 and SLIT2 in HeLa cells. (A–B) Membrane
localization of ROBO1/2 and (C) cytoplasmic/membrane
localization of SLIT2. Scale bars are 50 mm, magnifications: 40X.
(TIF)
Figure S2 Kaplan-Meier survival analysis (up to 5
years) of CACX patients. (A–C) Alteration of ROBO1, ROBO2
and SLIT2 significantly associated with poor overall survival. (D)
Alteration of atleast one of the ligand or receptors predicted poor
patient outcome. N: total number of samples.
(TIF)
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(XLS)
Table S2 Allelic alterations of ROBO1, ROBO2 and
SLIT2 in primary cervical lesions.
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Figure 4. Kaplan-Meier analysis of survival (up to 5 years) of CACX patients. Alterations of (A) SLIT2 and/or ROBO1 and (B) SLIT2 and/or
ROBO2 ligand-receptor pairs were significantly associated with poor patient outcome [OS]. (C) Representation of Cox Multivariate analyses of genetic,
clinical and etiological parameters in predicting outcome of CACX patients. N: total number of samples and P,0.05 denotes statistical significance.
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